Deep Currents Investment Group LLC Biomarin Pharmaceutical Inc Call Options Transaction History

Deep Currents Investment Group LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $16,382 - $18,956	189 Added 27.19%	884 $76,000
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $62,646 - $83,730	-714 Reduced 50.67%	695 $67,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $76,573 - $90,348	932 Added 195.39%	1,409 $11.9 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $10,722 - $13,027	150 Added 45.87%	477 $3.95 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $24,289 - $30,309	327 New	327 $2.52 Million

Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $3.92 Million - $7.14 Million	-54,500 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $2.77 Million - $4.32 Million	34,800 Added 176.65%	54,500 $6.72 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $661,981 - $889,611	-10,300 Reduced 34.33%	19,700 $1.67 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $1.53 Million - $1.93 Million	-22,700 Reduced 43.07%	30,000 $2.02 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $421,000 - $493,100	5,000 Added 10.48%	52,700 $4.68 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $3.82 Million - $5.06 Million	47,700 New	47,700 $4.06 Million

623

181M

1.73M

1.73M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Deep Currents Investment Group LLC, based on Form 13F filings with the SEC.

Stay updated on Deep Currents Investment Group LLC with notifications on news.